VentriPoint Diagnostics Ltd V.VPT

Faster, less expensive and providing cMRI levels.🚀

[jopatclo]

Hugh MacNaughtHugh MacNaught• Following• FollowingPresident and CEO at Ventripoint Diagnostics Ltd.President and CEO at Ventripoint Diagnostics Ltd.

1h • 1 hour ago

 

Great points Bart. Faster, less expensive and providing cMRI levels of accuracy make VMS+ a compelling option for clinical trials, particularly those monitoring right ventricle volumes and ejection fractions. AI enhanced echo is a more patient-friendly modality which improves patient recuitment and compliance thereby improving efficiency and reducing risk.

• 
• 

Venture Capital Fund, Startup, and Angel Investors ***Over 77,000 Members*** Meetings Every 60 DaysVenture Capital Fund, Startup, and Angel Investors ***Over 77,000 Members*** Meetings Every 60 DaysBart Hendriks • FollowingBart Hendriks • Following

3h • 3 hours ago

Join

Revolutionizing Cardiac Diagnostics: The Cost-Effective and Inclusive Power of Ventripoint VMS+ Over Traditional MRI in Clinical Trials

In the realm of cardiac diagnostics, the Ventripoint VMS+ system emerges as a transformative tool, offering a unique blend of efficiency, cost-effectiveness, and patient inclusivity. Here’s why researchers and clinicians are opting for VMS+ over traditional cardiac MRI:

High Precision with Lower Costs: Traditional cardiac MRIs are known for their steep costs, encompassing expensive imaging equipment, specialized facilities, and prolonged testing times. In contrast, the Ventripoint VMS+ leverages standard echocardiography equipment to provide MRI-equivalent heart measurements, significantly reducing costs and making it a financially viable option for extensive clinical trials.

Enhanced Efficiency: The lengthy process required for MRI scans often leads to increased trial durations and higher costs. VMS+ simplifies cardiac assessment, enabling rapid, on-the-spot evaluations and accelerating the trial process.

Improved Patient Experience: The daunting nature of MRI scans can deter patient participation. The non-invasive and patient-friendly approach of the VMS+ increases comfort and compliance, which is crucial for successful clinical trials.

Magnetless Technology: The VMS+ system utilizes magnetless technology, making it a safe option for patients with pacemakers or other metallic implants who are typically excluded from MRI studies. This inclusion broadens the potential patient population for clinical trials, enhancing the diversity and applicability of research findings.

Reliable Data Collection: VMS+'s advanced algorithms deliver consistent and repeatable cardiac measurements, providing robust and reliable data essential for precise clinical analysis.

Dramatic Cost Reductions: Clinical trials can achieve significant cost reductions by integrating the VMS+ system. The savings come not only from eliminating expensive MRI scans but also from reduced patient attrition and more efficient data collection processes.

Accessibility and Portability: The VMS+'s portable nature expands its usability across diverse clinical settings, further driving down logistical costs and facilitating broader geographic reach in trials.

In clinical trials, where managing costs without compromising quality is paramount, the Ventripoint VMS+ offers an innovative, cost-effective, and inclusive solution. Connect with us to explore how VMS+ is reshaping cardiac diagnostics, making advanced technology accessible and affordable for a wider range of patients!

#Ventripoint #ClinicalTrials #CardiacHealth #Innovation #MedicalDevices #Cardiology #PacemakerSafe #CRO

[jopatclo]

Close green 0.205 $.game on ats 248,715 total volume and 66,660 TSX-V Close Prices Last 3 Months Price/volumes not adjusted for restructures Date Ex Sym Open High Low Close Chg Total Vol #Tr Bid Ask V-TSX-V U-NEO ATS A-Alpha O-Omega